Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study. (21st June 2017)

• Record Type: Journal Article
• Authors: Reiser, Marcel; Borte, Michael; Huscher, Dörte; Baumann, Ulrich; Pittrow, David; Sommer, Claudia; Stangel, Martin; Fasshauer, Maria; Gold, Ralf; Hensel, Manfred
• Other Names: Abenhardt investigator.; Auerswald investigator.; Baer investigator.; Braun investigator.; Schulz investigator.; Cordes investigator.; Fronhoffs investigator.; Hamm investigator.; Hansen investigator.; Reeb investigator.; Heinrich investigator.; Herrenberger investigator.; Hilgendorf investigator.; Hübner investigator.; Hurtz investigator.; Josten investigator.; Klausmann investigator.; Körber investigator.; Kühn investigator.; Laws investigator.; Lerchenmüller investigator.; Lück investigator.; Meyer investigator.; Mohr investigator.; Nacke A. investigator.; Panagiotou investigator.; Plath investigator.; Porowski investigator.; Reichert investigator.; Sandner investigator.; Scheuermann investigator.; Schwarz investigator.; Schwarzer investigator.; Schwittay investigator.; Springer investigator.; Staiger investigator.; Stiegler investigator.; Vehling‐Kaiser investigator.; Welslau investigator.; Ziske investigator.; Blau investigator.; Borte investigator.; Faßhauer investigator.; Hensel investigator.; Illmer investigator.; Reiser investigator.; Salat investigator.; von Depka Prondzinski investigator.; Detering investigator.; Weide investigator.;
• Is Part Of: European journal of haematology. Volume 99:Number 2(2017)
• Page Start: 169
• Page End: 177
• Publication Date: 2017-06-21
• Subjects: chronic lymphatic leukaemia -- drug utilisation -- immune globulin -- infections -- intravenous -- multiple myeloma -- observational -- outcomes research -- patient‐related outcomes -- quality of life -- routine care -- secondary immunodeficiency -- subcutaneous; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12900
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: We aimed to describe the current management and outcomes of patients with secondary immunodeficiencies (SID) on intravenous (IV) or subcutaneous (SC) immunoglobulins (IG) as maintenance therapy to prevent infections. Methods: Non‐interventional, prospective study (average follow‐up 20.5 months). Results: Of the 307 SID patients (mean age 63.7±14.4 years, 52% males, in 31% IG newly initiated), 95.4% received IV IG (mean dosing interval 4.6 weeks, average dose 199 mg/kg per 4 weeks) and 4.6% were treated with SC IG (2.6 weeks, 343 mg/kg per 4 weeks). Median IG through level at first documentation was 5.8 g/L and did not differ between IV and SC treatment or between underlying malignancies. In 24.1% of patients, treatment was interrupted temporarily, over a mean of 11.6±6.3 months. In patients with newly initiated IG treatment the 82% overall infection rate prior to treatment dropped to 21% at 1 year. Conclusions: Under clinical practice conditions, IG replacement therapy in SID patients was feasible, diminished infection rates and improved quality of life. Average IG doses were relatively low. Tolerability of IV IG treatment was excellent.